[ad_1]
MRNA of Moderna Inc.,
said on Friday it was amending its supply agreement with Israel’s health ministry and would provide an additional 4 million doses of its experimental COVID-19 vaccine mRNA-1273. The amendment brings the total number of doses guaranteed by Israel to 6 million. The vaccine is currently pending review for emergency use authorization in the United States and has been submitted for approval in Europe. The company has initiated the ongoing regulatory review process with Israel’s health ministry, he said in a statement. The vaccine was found to be 94% effective in a preliminary analysis of a Phase 3 trial of 196 cases. The trial involves more than 30,000 participants and is being conducted with the NIAID part of the NIH and the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and of Man. Services. Moderna is also working on scaling up manufacturing and aims to deliver around 500 million doses per year and up to 1 billion doses per year from 2021. Shares were slightly lower before going to market , but have gained 704% since the start of the year, while the JSPDR ETF XBI S&P 500 Biotech,
gained 41% and the S&P 500 SPX,
[gained 13%.
[ad_2]
Source link